Physiological roles of amyloid-β and implications for its removal in alzheimer's disease

Drugs and Aging

Volumn 21, Issue 10, 2004, Pages 621-630

  Bishop, Glenda M ^a   Robinson, Stephen R ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN; BRAIN NERVE CELL; CELL GROWTH; CELL PROTECTION; CELL SURVIVAL; COGNITION; CYTODIAGNOSIS; DEMENTIA; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; MEMORY CONSOLIDATION; NERVE CELL DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SENILE PLAQUE; SYNAPSE; TISSUE DISTRIBUTION; UBIQUITINATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; DRUG THERAPY; HUMANS;

EID: 4344626024     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200421100-00001     Document Type: Review

References (91)

1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297 (5580): 353-6
2. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991; 6 (4): 487-98
3. Robinson SR, Bishop GM. Aβ as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease. Neurobiol Aging 2002; 23 (6): 1051-72
4. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400 (6740): 173-7
5. Check E. Nerve inflammation halts trial for Alzheimer's drug [letter]. Nature 2002; 415 (6871): 462
6. Kunicki S, Richardson J, Mehta PD, et al. The effects of age, apolipoprotein E phenotype and gender on the concentration of amyloid-β (Aβ)40, Aβ42, apolipoprotein E and transthyretin in human cerebrospinal fluid. Clin Biochem 1998; 31 (5): 409-15
7. Shoji M, Matsubara E, Kanai M, et al. Combination assay of CSF tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease. J Neurol Sci 1998; 158 (2): 134-40
8. Tamaoka A, Fukushima T, Sawamura N, et al. Amyloid β protein in plasma from patients with sporadic Alzheimer's disease. J Neurol Sci 1996; 141 (1-2): 65-8
9. Coulson EJ, Paliga K, Beyreuther K, et al. What the evolution of the amyloid protein precursor supergene family tells us about its function. Neurochem Int 2000; 36 (3): 175-84
10. Luo Y, Bolon B, Damore MA, et al. BACE1 (β-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time. Neurobiol Dis 2003; 14 (1): 81-8
11. Hertz L, Dringen R, Schousboe A, et al. Astrocytes: glutamate producers for neurons. J Neurosci Res 1999; 57 (4): 417-28
12. Ida N, Hartmann T, Pantel J, et al. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 1996; 271 (37): 22908-14
13. Shoji M, Kanai M, Matsubara E, et al. The levels of cerebrospinal fluid Aβ40 and Aβ42(43) are regulated age-dependently. Neurobiol Aging 2001; 22 (2): 209-15
14. Blennow K, Sjogren M, Andreasen N. Usefulness of CSF total tau, Aβ42 and phospho tau as biomarkers for Alzheimer's disease. In: Iqbal K, Winblad B, editors. Alzheimer's disease and related disorders: research advances. Bucharest: 'Ana Asian' International Academy of Aging, 2003: 247-58
15. Mayeux R, Tang MX, Jacobs DM, et al. Plasma amyloid β-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol 1999; 46 (3): 412-6
16. Mayeux R, Honig LS, Tang MX, et al. Plasma Aβ40 and Aβ42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 2003; 61 (9): 1185-90
17. Li QX, Whyte S, Tanner JE, et al. Secretion of Alzheimer's disease Aβ amyloid peptide by activated human platelets. Lab Invest 1998; 78 (4): 461-9
18. Armogida M, Petit A, Vincent B, et al. Endogenous β-amyloid production in presenilin-deficient embryonic mouse fibroblasts. Nat Cell Biol 2001; 3 (11): 1030-3
19. Shibata M, Yamada S, Kumar SR, et al. Clearance of Alzheimer's amyloid-β(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000; 106 (12): 1489-99
20. Savage MJ, Trusko SP, Howland DS, et al. Turnover of amyloid β-protein in mouse brain and acute reduction of its level by phorbol ester. J Neurosci 1998; 18 (5): 1743-52
21. Mackic JB, Stins M, McComb JG, et al. Human blood-brain barrier receptors for Alzheimer' s amyloid-β 1-40: asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J Clin Invest 1998; 102 (4): 734-43
22. Deane R, Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003; 9 (7): 907-13
23. Pan W, Solomon B, Maness LM, et al. Antibodies to β-amyloid decrease the blood-to-brain transfer of β-amyloid peptide. Exp Biol Med (Maywood) 2002; 227 (8): 609-15
24. Dawson GR, Seabrook GR, Zheng H, et al. Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the β-amyloid precursor protein. Neuroscience 1999; 90 (1): 1-13
25. Seabrook GR, Smith DW, Bowery BJ, et al. Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein. Neuropharmacology 1999; 38 (3): 349-59
26. Huber G, Martin JR, Loffler J, et al. Involvement of amyloid precursor protein in memory formation in the rat: an indirect antibody approach. Brain Res 1993; 603 (2): 348-52
27. Mileusnic R, Lancashire CL, Johnston AN, et al. APP is required during an early phase of memory formation. Eur J Neurosci 2000; 12 (12): 4487-95
28. Dewachter I, Reverse D, Caluwaerts N, et al. Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice. J Neurosci 2002; 22 (9): 3445-53
29. Koistinaho M, Ort M, Cimadevilla JM, et al. Specific spatial learning deficits become severe with age in β-amyloid precursor protein transgenic mice that harbor diffuse β-amyloid deposits but do not form plaques. Proc Natl Acad Sci USA 2001; 98 (25): 14675-80
30. Itoh A, Akaike T, Sokabe M, et al. Impairments of long-term potentiation in hippocampal slices of β-amyloid-infused rats. Eur J Pharmacol 1999; 382 (3): 167-75
31. Raymond CR, Ireland DR, Abraham WC. NMDA receptor regulation by amyloid-β does not account for its inhibition of LTP in rat hippocampus. Brain Res 2003; 968 (2): 263-72
32. Wu J, Anwyl R, Rowan MJ. β-amyloid-(1-40) increases long-term potentiation in rat hippocampus in vitro. Eur J Pharmacol 1995; 284 (3): R1-3
33. Kim JH, Anwyl R, Suh YH, et al. Use-dependent effects of amyloidogenic fragments of (β)-amyloid precursor protein on synaptic plasticity in rat hippocampus in vivo. J Neurosci 2001; 21 (4): 1327-33
34. Trubetskaya VV, Stepanichev MY, Onufriev MV, et al. Administration of aggregated β-amyloid peptide (25-35) induces changes in long-term potentiation in the hippocampus in vivo. Neurosci Behav Physiol 2003; 33 (2): 95-8
35. Morton RA, Kuenzi FM, Fitzjohn SM, et al. Impairment in hippocampal long-term potentiation in mice under-expressing the Alzheimer's disease related gene presenilin-1. Neurosci Lett 2002; 319 (1): 37-40
36. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416 (6880): 535-9
37. 1-42 binds selectively and with picomolar affinity to α7 nicotinic acetylcholine receptors. J Neurochem 2000; 75 (3): 1155-61
38. Freir DB, Herron CE. Nicotine enhances the depressive actions of Aβ1-40 on long-term potentiation in the rat hippocampal CA1 region in vivo. J Neurophysiol 2003; 89 (6): 2917-22
39. Mattson MP, Partin J, Begley JG. Amyloid β-peptide induces apoptosis-related events in synapses and dendrites. Brain Res 1998; 807 (1-2): 167-76
40. Dougherty JJ, Wu J, Nichols RA. β-amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. J Neurosci 2003; 23 (17): 6740-7
41. Kamenetz F, Tomita T, Hsieh H, et al. APP processing and synaptic function. Neuron 2003; 37 (6): 925-37
42. Ikegaya Y, Matsuura S, Ueno S, et al. β-amyloid enhances glial glutamate uptake activity and attenuates synaptic efficacy. J Biol Chem 2002; 277 (35): 32180-6
43. Koudinov AR, Koudinova NV. Amyloid β protein restores hippocampal long term potentiation: a central role for cholesterol. Neurobiol Lipids 2003; 1 (8): 45-6
44. Whitson JS, Selkoe DJ, Cotman CW. Amyloid β protein enhances the survival of hippocampal neurons in vitro. Science 1989; 243 (4897): 1488-90
45. Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science 1990; 250 (4978): 279-82
46. Wang C, Wurtman RJ, Lee RK. Amyloid precursor protein and membrane phospholipids in primary cortical neurons increase with development, or after exposure to nerve growth factor or Aβ(1-40). Brain Res 2000; 865 (2): 157-67
47. Phinney AL, Deller T, Stalder M, et al. Cerebral amyloid induces aberrant axonal sprouting and ectopic terminal formation in amyloid precursor protein transgenic mice. J Neurosci 1999; 19 (19); 8552-9
48. Wujek JR, Dority MD, Frederickson RC, et al. Deposits of Aβ fibrils are not toxic to cortical and hippocampal neurons in vitro. Neurobiol Aging 1996; 17 (1): 107-13
49. DeWitt DA, Silver J. Regenerative failure: a potential mechanism for neuritic dystrophy in Alzheimer's disease. Exp Neurol 1996; 142 (1); 103-10
50. Plant LD, Boyle JP, Smith IF, et al. The production of amyloid β peptide is a critical requirement for the viability of central neurons. J Neurosci 2003; 23 (13): 5531-5
51. Bishop GM, Robinson SR. Human Aβ1-42 reduces iron-induced toxicity in rat cerebral cortex. J Neurosci Res 2003; 73 (3): 316-23
52. Bishop GM, Robinson SR. Neurotoxic and neuroprotective: the paradox of amyloid-metal complexes in vivo. In: 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 Jul 20-25; Stockholm. Neurobiol Aging 2002; 23 Suppl. 1S: S26
53. Zou K, Gong JS, Yanagisawa K, et al. A novel function of monomeric amyloid β-protein serving as an antioxidant molecule against metal-induced oxidative damage. J Neurosci 2002; 22 (12): 4833-41
54. Butterfield DA. Amyloid β-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain: a review. Free Radic Res 2002; 36 (12): 1307-13
55. Kontush A, Berndt C, Weber W, et al. Amyloid-β is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. Free Radic Biol Med 2001; 30 (1): 119-28
56. Atwood CS, Moir RD, Huang X, et al. Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 1998; 273 (21): 12817-26
57. Garzon-Rodriguez W, Yatsimirsky AK, Glabe CG. Binding of Zn(II), Cu(II), and Fe(II) ions to Alzheimer's Aβ peptide studied by fluorescence. Bioorg Med Chem Lett 1999; 9 (15): 2243-8
58. Mantyh PW, Ghilardi JR, Rogers S, et al. Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of β-amyloid peptide. J Neurochem 1993; 61 (3): 1171-4
59. Nunomura A, Perry G, Aliev G, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001; 60 (8): 759-67
60. Kontush A, Donarski N, Beisiegel U. Resistance of human cerebrospinal fluid to in vitro oxidation is directly related to its amyloid-β content. Free Radic Res 2001; 35 (5): 507-17
61. Kawahara M, Muramoto K, Kobayashi K, et al. Aluminum promotes the aggregation of Alzheimer's amyloid β-protein in vitro. Biochem Biophys Res Commun 1994; 198 (2): 531-5
62. Smith MA, Harris PL, Sayre LM, et al. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A 1997; 94 (18): 9866-8
63. Lovell MA, Robertson JD, Teesdale WJ, et al. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 1998; 158 (1): 47-52
64. Golabek A, Marques MA, Lalowski M, et al. Amyloid β binding proteins in vitro and in normal human cerebrospinal fluid. Neurosci Lett 1995; 191 (1-2): 79-82
65. Oyama R, Yamamoto H, Titani K. Glutamine synthetase, hemoglobin α-chain, and macrophage migration inhibitory factor binding to amyloid β-protein: their identification in rat brain by a novel affinity chromatography and in Alzheimer's disease brain by immunoprecipitation. Biochim Biophys Acta 2000; 1479 (1-2): 91-102
66. de Haas CJ. New insights into the role of serum amyloid P component, a novel lipopolysaccharide-binding protein. FEMS Immunol Med Microbiol 1999; 26 (3-4): 197-202
67. de Haas CJ, van Leeuwen EM, van Bommel T, et al. Serum amyloid P component bound to Gram-negative bacteria prevents lipopolysaccharide-mediated classical pathway complement activation. Infect Immun 2000; 68 (4): 1753-9
68. Andersen O, Vilsgaard Ravn K, Juul Sorensen I, et al. Serum amyloid P component binds to influenza A virus haemagglutinin and inhibits the virus infection in vitro. Scand J Immunol 1997; 46 (4): 331-7
69. Bishop GM, Robinson SR. The amyloid hypothesis: let sleeping dogmas lie? Neurobiol Aging 2002; 23 (6): 1101-5
70. Balin BJ, Gerard HC, Arking EJ, et al. Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. Med Microbiol Immunol (Berl) 1998; 187 (1): 23-42
71. Sigurdssón EM, Scholtzova H, Mehta PD, et al. Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 2001; 159 (2): 439-47
72. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6 (8): 916-9
73. Munch G, Robinson SR. Potential neurotoxic inflammatory responses to Aβ vaccination in humans. J Neural Transm 2002; 109 (7-8): 1081-7
74. Robinson SR, Bishop GM, Lee H-G, et al. Lessons from the AN 1792 Alzheimer vaccine: lest we forget. Neurobiol Aging 2004; 25: 609-16
75. Robinson SR, Bishop GM, Munch G. Alzheimer vaccine: amyloid-β on trial. Bioessays 2003; 25 (3): 283-8
76. Schenk D. Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 2002; 3 (10): 824-8
77. Hyman BT, Smith C, Buldyrev I, et al. Autoantibodies to amyloid-β and Alzheimer's disease. Ann Neurol 2001; 49 (6): 808-10
78. Du Y, Dodel R, Hampel H, et al. Reduced levels of amyloid β-peptide antibody in Alzheimer disease. Neurology 2001; 57 (5): 801-5
79. Weksler ME, Relkin N, Turkenich R, et al. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 2002; 37 (7): 943-8
80. Hock C, Konietzko U, Papassotiropoulos A, et al. Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease. Nat Med 2002; 8 (11): 1270-5
81. Monsonego A, Zota V, Kami A, et al. Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease. J Clin Invest 2003; 112 (3): 415-22
82. Nath A, Hall E, Tuzova M, et al. Autoantibodies to amyloid β-peptide (Aβ) are increased in Alzheimer's disease patients and Aβ antibodies can enhance Aβ neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolecular Med 2003; 3 (1): 29-39
83. McGreevy K, Wang DS, Dickson DW. Is lowering amyloid levels a therapeutic target for Alzheimer's disease: insights from macrophage-mediated resorption of amyloid in cortical infarcts. In: Iqbal K, Winblad B, editors. Alzheimer's disease and related disorders: research advances. Bucharest: 'Ana Aslan' International Academy of Aging, 2003: 569-80
84. Cai H, Wang Y, McCarthy D, et al. BACE1 is the major β-secretase for generation of Aβ peptides by neurons. Nat Neurosci 2001; 4 (3): 233-4
85. Roberds SL, Anderson J, Basi G, et al. BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 2001; 10 (12): 1317-24
86. Luo Y, Bolon B, Kahn S, et al. Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation. Nat Neurosci 2001; 4 (3): 231-2
87. Yu H, Saura CA, Choi SY, et al. APP processing and synaptic plasticity in presenilin-1 conditional knockout mice. Neuron 2001; 31 (5): 713-26
88. Feng R, Rampon C, Tang YP, et al. Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces. Neuron 2001; 32 (5): 911-26
89. Ohno M, Sametsky EA, Younkin LH, et al. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 2004; 41 (1): 27-33
90. Gong Y, Chang L, Viola KL, et al. Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A 2003; 100 (18): 10417-22
91. Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300 (5618): 486-9